PUBLIC LECTURE: Public Lecture Dr Dan Burns
|Public Lecture Dr Dan Burns : ‘25 Years of Alzheimer’s disease Research and Clinical Development: How we got here and where do we go’
During his >30 years in the pharmaceutical industry Dr Dan Burns has worked across the continuum of discovery and development of medicines and their post approval life cycle management. He has led in house scientific departments at large pharmaceutical companies while also building successful collaborations with the biotechnology industry, government, patient advocacy groups and public private partnerships.
As a senior executive at Zinfandel Pharmaceuticals, Dan leads a team in alliance with Takeda Pharmaceuticals responsible for the design and execution of a global phase 3 registration study to simultaneously qualify a genetic biomarker and evaluate a therapeutic to delay the onset of Alzheimer’s disease. Prior to his appointment at Zinfandel Pharmaceuticals, he served in senior management positions at GlaxoSmithKline (GSK), most recently as Senior Vice President, Pharmacogenomics. In addition to managing international line functions, he took a leadership role in working across therapeutic areas to integrate pharmacogenetics throughout the R&D organisation. Prior to joining GSK he held positions of increasing responsibility at Hoffmann-La Roche, Inc.
Dan Burns has published widely throughout his career and has been an invited speaker on the topic of pharmacogenetics, biomarkers and innovation in drug development at numerous scientific conferences. These include meetings organized by the US Food and Drug Administration (FDA), the National Institutes of Health (NIH), Drug Information Association (DIA) and the Keystone Symposium. In addition, he has provided consultation services to the pharmaceutical and diagnostic industries.
Dr Burns holds a BS (Biology), MA (Zoology) and PhD (Molecular, Cellular and Developmental Biology) from Indiana University. He did his post-doctoral research at Hoffmann-La Roche, Inc. investigating protein structure function relationships.
JOIN US FROM 3.20PM!
This lecture is part of a session open to the general public and will commence with a THREE-MINUTE THESIS COMPETITION (HONS & EARLY PHD STUDENTS) from 3.20PM.
ALL ARE WELCOME!
DR DAN BURNS Zinfandel Pharmaceuticals, Inc USA
Harry Perkins Institute of Medical Research
Fri, 30 Nov 2018 16:20
Fri, 30 Nov 2018 17:20
Lindy Fitzgerald <[email protected]>
Mon, 05 Nov 2018 04:27
- Locations of venues on the Crawley and Nedlands campuses are
available via the Campus Maps website.
- Download this event as:
Mail this event: